ProQR Therapeutics (PRQR) Projected to Release Earnings on Thursday

Posted by Francis Steltz on Aug 4th, 2026

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect ProQR Therapeutics to post earnings of ($0.1303) per share and revenue of $4.5610 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 12:30 PM ET.

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $5.19 million. ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%. On average, analysts expect ProQR Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ProQR Therapeutics Trading Up 3.8%

Shares of NASDAQ PRQR traded up $0.07 during trading hours on Tuesday, hitting $1.77. 291,863 shares of the company traded hands, compared to its average volume of 710,216. The stock has a market capitalization of $187.01 million, a price-to-earnings ratio of -3.57 and a beta of 0.07. The company’s 50 day moving average price is $1.67 and its 200 day moving average price is $1.64. ProQR Therapeutics has a 12 month low of $1.33 and a 12 month high of $3.10.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wall Street Zen cut ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. JonesTrading lowered their price target on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Chardan Capital dropped their price objective on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Finally, Weiss Ratings downgraded ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Check Out Our Latest Stock Report on PRQR

Insider Activity

In related news, CEO Boer Daniel Anton De purchased 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were purchased at an average cost of $1.74 per share, with a total value of $261,000.00. Following the purchase, the chief executive officer owned 300,000 shares of the company’s stock, valued at $522,000. This represents a 100.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bart Filius bought 150,000 shares of the firm’s stock in a transaction on Friday, July 17th. The stock was acquired at an average cost of $1.72 per share, for a total transaction of $258,000.00. Following the completion of the purchase, the director directly owned 300,000 shares in the company, valued at approximately $516,000. This represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 600,000 shares of company stock worth $988,500. 8.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. lifted its stake in shares of ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares during the last quarter. Guggenheim Capital LLC acquired a new stake in shares of ProQR Therapeutics during the fourth quarter valued at about $35,000. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics in the 4th quarter worth approximately $51,000. Simplex Trading LLC increased its holdings in ProQR Therapeutics by 44,169.0% in the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 44,169 shares during the last quarter. Finally, Persistent Asset Partners Ltd lifted its stake in ProQR Therapeutics by 24.5% during the fourth quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 8,874 shares in the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

About ProQR Therapeutics

(Get Free Report)

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.